Literature DB >> 8123396

Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure.

R A Cooper1, V R Maddineni, R K Mirakhur, J M Wierda, M Brady, K T Fitzpatrick.   

Abstract

We have studied the onset and duration of action and pharmacokinetics of rocuronium bromide (Org 9426) during anaesthesia with nitrous oxide, fentanyl and isoflurane after a single bolus dose of rocuronium 0.6 mg kg-1 in nine patients with chronic renal failure requiring regular haemodialysis, and in nine healthy control patients. Blood samples were collected over 390 min and concentrations of rocuronium and its putative metabolites measured using HPLC. Onset time for maximum block, duration of clinical relaxation (T1(25)) and recovery index, were 61 (SD 25.0) s and 65 (16.4) s, 55 (26.9) min and 42 (9.3) min and 28 (12.3) min and 19 (8.8) min, respectively, for patients with and without renal failure. The time for TOF ratio to return spontaneously to 0.7 was 99 (41.1) min and 73 (24.2) min, respectively, in the two groups. None of these differences was significant. The pharmacokinetic data were best described by a three-exponential equation. There were significant differences between patients with and without renal failure in the rates of clearance (2.5 (1.1) ml kg-1 min-1 and 3.7 (1.4) ml kg-1 min-1, respectively) and the mean residence times (97.1 (48.7) min and 58.3 (9.6) min) P < 0.05). The differences in other kinetic parameters were not significant. We conclude that the effects of rocuronium may be prolonged in patients with renal disease, because of a decreased clearance of the drug.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8123396     DOI: 10.1093/bja/71.2.222

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  12 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Continuous infusion of rocuronium in a paediatric intensive care unit.

Authors:  J D Tobias
Journal:  Can J Anaesth       Date:  1996-04       Impact factor: 5.063

Review 3.  Newer neuromuscular blocking agents: how do they compare with established agents?

Authors:  H J Sparr; T M Beaufort; T Fuchs-Buder
Journal:  Drugs       Date:  2001       Impact factor: 9.546

4.  Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models.

Authors:  Kenichi Masui; Sayaka Ishigaki; Atsuko Tomita; Hiroshi Otake
Journal:  J Anesth       Date:  2018-08-11       Impact factor: 2.078

Review 5.  Clinical pharmacokinetics of rocuronium bromide.

Authors:  K S Khuenl-Brady; H Sparr
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

6.  Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion.

Authors:  Yutaka Oda
Journal:  J Anesth       Date:  2017-08-21       Impact factor: 2.078

7.  Reversal of rocuronium-induced neuromuscular block by sugammadex is independent of renal perfusion in anesthetized cats.

Authors:  Lonneke M Staals; Hans D de Boer; Jan van Egmond; Frank Hope; Francien van de Pol; Anton H Bom; Jacques J Driessen; Leo H D J Booij
Journal:  J Anesth       Date:  2011-01-12       Impact factor: 2.078

Review 8.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

9.  The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen.

Authors:  Tomoki Sasakawa; Kenichi Masui; Tomiei Kazama; Hiroshi Iwasaki
Journal:  J Anesth       Date:  2016-04-20       Impact factor: 2.078

10.  Sugammadex rescue following prolonged rocuronium neuromuscular blockade with 'recurarisation' in a patient with severe renal failure.

Authors:  Steven Lobaz; Mario Sammut; Anand Damodaran
Journal:  BMJ Case Rep       Date:  2013-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.